The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the ...

Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes ...

Talphera (TLPH) announced that following a meeting with the FDA, the agency has agreed to review a Prior Approval Supplement requesting a reduction in the number of patients in the NEPHRO CRRT ...

(RTTNews) - Specialty pharmaceutical company Talphera, Inc. (TLPH), Monday announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously ...

A SOFA score of 12 or higher at ICU admission is associated with an increased risk for hospital mortality among critically ill patients with COVID-19 and AKI requiring CRRT. The Sequential Organ ...

SAN MATEO, Calif., Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative ...

The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study ...